Epoetin β once-weekly therapy in anemic patients with solid tumors and non-myeloid hematological malignancies receiving chemotherapy

Oncology

Volumn 74, Issue 1-2, 2008, Pages 112-118

  Spaëth, Dominique ^a   Desablens, Bernard ^b   Rodon, Philippe ^c   Mennecier, Bertrand ^d   Oudard, Stéphane ^e   Moullet, Isabelle ^f   Ghomari, Kamel ^g   Bergougnoux, Loïc ^h   Bleuzen, Pascal ^h   Jenabian, Arash ^h   Ifrah, Norbert ⁱ  

^a Centre d'Oncologie de Gentilly   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c Centre Hospitalier de Blois   (France)

^d UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^e HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^f Clinique de la Sauvegarde   (France)

^g Centre Hospitalier de Beauvais   (France)

^h F Hoffmann La Roche   (France)

ⁱ ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Anemia; Cancer; Chemotherapy, once weekly; Epoetin

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BREAST TUMOR; CANCER CHEMOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART INFARCTION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; LUNG TUMOR; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELOMA; NAUSEA; NEUTROPENIA; OVARY TUMOR; PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VASCULAR DISEASE; VEIN THROMBOSIS; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMATOLOGIC NEOPLASMS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES;

EID: 46249114388     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000139139     Document Type: Article

References (16)

1. Ludwig H, Van Belle S, Barrett-Lee P, Birgegård G, Bokemeyer C, Gascón P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D: The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-2306.
2. Oberhoff C, Neri B, Amadori D, Petry KU, Gamucci T, Rebmann U, Nowrousian MR, Voigtmann R, Monfardini S, Armand JP, Herrmann R, Netter-Pinon J, Tubiana-Mathieu N, Zwierzina H: Recombinant human erythropoietin in the treatment of chemotherapy-induced anaemia and prevention of transfusion requirement associated with solid tumors: a randomized, controlled study. Ann Oncol 1998;9:255-260.
3. Österborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, Messinger D; Epoetin Beta Hematology Study Group: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-2494.
4. Boogaerts M, Coiffier B, Kainz C; Epoetin Beta QOL Working Group: Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-995.
5. Boogaerts M, Oberhoff C, Ten Bokkel Huinink W, Nowrousian MR, Hayward CR, Burger HU: Epoetin beta (NeoRecormon®) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a meta-analysis. Anticancer Res 2006;26:479-484.
6. Pronzato P, Jassem J, Mayordomo J: Epoetin beta therapy in patients with solid tumours. Crit Rev Oncol Hematol 2006;58:46-52.
7. Cornes P, Boiangiu I: The role of epoetin beta in the treatment of anaemia in patients with gynaecological malignancies. Anticancer Res 2007;27:513-522.
8. Cazzola M, Beguin Y, Kloczko J, Spicka I, Coiffier B: Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122:386-393.
9. Glaspy J, Beguin Y: Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon®). Oncology 2005;69(suppl 2):8-16.
10. Aapro M, Barnadas A, Leonard RC, Marangolo M, Untch M: Effects of epoetin beta treatment in patients with metastatic breast cancer receiving chemotherapy (abstract 6095). Breast Cancer Res Treat 2006;100(suppl 1):S287.
11. Pirker R, Lehnert M, Minar W: Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy. Lung Cancer 2007;55:89-94.
12. Coiffier B, Guastalla J-P, Pujade-Lauraine E, Bastit P, Anemia Study Group: Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy: results of a retrospective survey. Eur J Cancer 2001;37:1617-1623.
13. Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU: Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the BRAVE study. J Clin Oncol 2008;26:592-598.
14. Coiffier B, Boogaerts M, Aapro M, Hayward C, Burger H-U: Effect of treatment with epoetin beta on thromboembolic events in anemic patients with cancer: a meta-analysis. Supportive Cancer Therapy 2006;4:49-55.
15. Bokemeyer C, Aapro MS, Courdi A, Foubert J, Link H, Österborg A, Repetto L, Soubeyran P;European Organisation for Research and Treatment of Cancer (EORTC) Taskforce for the Elderly: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-270.
16. Wazny LD, Stojimirovic BB, Heidenheim P, Blake PG: Factors influencing erythropoietin compliance in peritoneal dialysis patients. Am J Kidney Dis 2002;40:623-628.